Stocks · News reference
Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.73) by 4.11 percent. This is a 1.3 percent increase over losses of $(0.77) per share from
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-17 AccNo: 0001193125-26-354092 Size: 175 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarBTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $46 price target.
Read original at benzinga